TY - JOUR
T1 - Epidemiology of atopic dermatitis in adults
T2 - Results from an international survey
AU - Barbarot, S.
AU - Auziere, S.
AU - Gadkari, A.
AU - Girolomoni, G.
AU - Puig, L.
AU - Simpson, E. L.
AU - Margolis, D. J.
AU - de Bruin-Weller, M.
AU - Eckert, L.
N1 - Funding Information:
This study was funded by Regeneron Pharmaceuticals, Inc. and Sanofi.
Funding Information:
S. Barbarot has received research grants from Pierre Fabre Laboratory and Fondation pour la dermatite atopique; personal fees from Bioderma, Laboratoire La Roche Posay, Sanofi-Genzyme, Novalac, Ferring; and nonfinancial support from Abbvie, Novartis, Janssen. A. Gadkari is an employee of and stockholder in Regeneron Pharmaceuticals, Inc. S. Auziere is an employee of Kantar Health, who received funding from Sanofi to conduct the study. E. Simpson’s institution has received grants/research funding from Amgen, Inc, Anacor Pharmaceuticals Inc., Celgene Corporation, Chugai Pharma US, LLC, Eli Lilly and Company, Galderma Research and Development, Genen-tech Inc., MedImmune LLC, Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Tioga Pharmaceuticals Inc, and is a consultant for Regeneron Pharmaceuticals, Inc., Sanofi, Anacor, Celgene Corporation, Galderma Research and Development, Genentech, MedImmune LLC, Pfizer Inc., AbbVie, Dermira, and Valeant. M. de Bruin-Weller is a consultant for Regeneron Pharmaceuticals, Inc., Sanofi Genzyme; an advisory board member for AbbVie, Anacor, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme; and principal investigator for AbbVie, Regeneron Pharmaceuticals, Inc., Roche, Sanofi Genzyme. G. Girolomoni has been principal investigator in clinical trials sponsored by and/or and has received personal fees from AbbVie, Abiogen, Almirall, Amgen, Bayer, Biogen, Celgene, Eli-Lilly, Galderma, Hospira, Janssen, Leo Pharma, Merck, MSD, Mundipharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Samsung, Sandoz, Sanofi, and Sun Pharma. L. Puig has received consultancy honoraria from and participated in clinical trials sponsored by Regeneron Pharmaceuticals, Inc., and Sanofi. L. Eckert is an employee of and stockholder in Sanofi.
PY - 2018/6
Y1 - 2018/6
N2 - Background: There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). Objective: To estimate the prevalence of AD in adults and by disease severity. Methods: This international, cross-sectional, web-based survey was performed in the United States, Canada, France, Germany, Italy, Spain, United Kingdom, and Japan. Adult members of online respondent panels were sent a questionnaire for AD identification and severity assessment; demographic quotas ensured population representativeness for each country. A diagnosis of AD required subjects to be positive on the modified UK Working Party/ISAAC criteria and self-report of ever having an AD diagnosis by a physician. The proportion of subjects with AD who reported being treated for their condition was determined and also used to estimate prevalence. Severity scales were Patient-Oriented SCORAD, Patient-Orientated Eczema Measure, and Patient Global Assessment. Results: Among participants by region, the point prevalence of adult AD in the overall/treated populations was 4.9%/3.9% in the US, 3.5%/2.6% in Canada, 4.4%/3.5% in the EU, and 2.1%/1.5% in Japan. The prevalence was generally lower for males vs females, and decreased with age. Regional variability was observed within countries. Severity varied by scale and region; however, regardless of the scale or region, proportion of subjects reporting severe disease was lower than mild or moderate disease. Conclusions: Prevalence of adult AD ranged from 2.1% to 4.9% across countries. Severe AD represented a small proportion of the overall AD population regardless of measure or region.
AB - Background: There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). Objective: To estimate the prevalence of AD in adults and by disease severity. Methods: This international, cross-sectional, web-based survey was performed in the United States, Canada, France, Germany, Italy, Spain, United Kingdom, and Japan. Adult members of online respondent panels were sent a questionnaire for AD identification and severity assessment; demographic quotas ensured population representativeness for each country. A diagnosis of AD required subjects to be positive on the modified UK Working Party/ISAAC criteria and self-report of ever having an AD diagnosis by a physician. The proportion of subjects with AD who reported being treated for their condition was determined and also used to estimate prevalence. Severity scales were Patient-Oriented SCORAD, Patient-Orientated Eczema Measure, and Patient Global Assessment. Results: Among participants by region, the point prevalence of adult AD in the overall/treated populations was 4.9%/3.9% in the US, 3.5%/2.6% in Canada, 4.4%/3.5% in the EU, and 2.1%/1.5% in Japan. The prevalence was generally lower for males vs females, and decreased with age. Regional variability was observed within countries. Severity varied by scale and region; however, regardless of the scale or region, proportion of subjects reporting severe disease was lower than mild or moderate disease. Conclusions: Prevalence of adult AD ranged from 2.1% to 4.9% across countries. Severe AD represented a small proportion of the overall AD population regardless of measure or region.
KW - atopic dermatitis
KW - epidemiology
KW - prevalence
KW - severity
UR - http://www.scopus.com/inward/record.url?scp=85041896926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041896926&partnerID=8YFLogxK
U2 - 10.1111/all.13401
DO - 10.1111/all.13401
M3 - Article
C2 - 29319189
AN - SCOPUS:85041896926
VL - 73
SP - 1284
EP - 1293
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
SN - 0108-1675
IS - 6
ER -